LY3323795 + itraconazole

LY3323795 + itraconazole refers to the coadministration of LY3323795, an investigational, BACE1-selective small molecule inhibitor under development by Eli Lilly for the treatment of Alzheimer's disease, and itraconazole, a marketed triazole antifungal agent. LY3323795 acts by selectively inhibiting β-site amyloid precursor protein cleaving enzyme 1 (BACE1), intended to reduce β-amyloid plaque formation, an early pathogenic step in Alzheimer’s disease. Itraconazole is approved for the treatment of various systemic and superficial fungal infections and acts through inhibition of fungal cytochrome P450-dependent 14α-demethylase, disrupting the synthesis of ergosterol, an essential component of fungal cell membranes. The combination has been studied specifically to assess potential pharmacokinetic interactions—particularly via the cytochrome P450 3A4 (CYP3A4) pathway, as itraconazole is a known CYP3A4 inhibitor and may alter LY3323795 metabolism[2][3][4][5].

Other names

itraconazole